Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, delivered via a proprietary controlled- release carrier intended to resolve metastatic breast cancer bone lesions, inhibit pain while ...
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...
The president-elect’s choice of Robert F. Kennedy Jr., a vaccine skeptic who wants to disrupt U.S. health agencies, sent ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback